Skip to main content
. Author manuscript; available in PMC: 2015 Mar 12.
Published in final edited form as: HIV Clin Trials. 2014 Nov-Dec;15(6):246–260. doi: 10.1310/hct1506-246

Figure 1.

Figure 1

Calculated creatinine clearance (CrCl) over time by treatment group. Continuous line represents treatment arm A (zidovudine/lamivudine + efavirenz [ZDV/3TC + EFV]) dotted line represents treatment arm C (tenofovir/emtricitabine + efavirenz [TDF/FTC + EFV]). Statistically significant differences in CrCl were found at week 24, 48, 72, 144, and 192 by Wilcoxon test.